首页 > 市场调查报告书 > 製药

DDS

市场调查报告书

商品编码

1881254

药物递送合作与许可协议（2019-2025）

Drug Delivery Collaboration and Licensing Deals 2019-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

"药物递送合作与许可协议" 全面深入地分析了全球领先的生物製药公司签署的药物递送协议，并提供前所未有的资讯取得管道。

这份经过全面修订和更新的报告详细介绍了2019年至2025年间的药物递送协议。

本报告深入分析了企业签署药物递送协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，逐步推进到成果的商业化。

本报告涵盖合作研发、研究和授权等内容。

本报告包含自2019年以来公布的1246项药物递送协议的完整列表，其中包括可用的财务条款以及各方披露的实际药物递送合作协议的在线记录链接。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了药物递送领域的交易活动。

第一章概述了本报告。

第二章概述了自 2019 年以来的药物递送交易活动。

第三章概述了自 2019 年以来主要的药物递送交易，并依交易总额列出。

第四章提供了药物递送领域交易活动最活跃的前 25 家公司的完整列表，并附有简要概述，以及药物递送交易和公开合约文件的完整列表。

第五章对自 2019 年 1 月以来已完成或已宣布的、且有公开合约文件的药物递送交易进行了全面深入的审查。

第六章对自2019年1月以来已达成或宣布的药物递送领域合作协议进行了全面深入的回顾。本章以具体的药物递送技术类型进行组织。

报告还包含大量表格和图表，显示了自2019年以来药物递送技术交易的趋势和动态。

此外，我们还提供了一个全面的交易目录，依公司名称（A-Z）、交易类型和治疗靶点进行分类。每个交易标题都透过网路连结指向线上交易记录和可用的协议文件，方便用户根据需要轻鬆存取每个协议文件。

主要优势

"药物递送技术合作与授权协议" 报告提供读者以下主要优势：

了解 2019 年及以后的交易趋势
浏览药物递送合作与授权协议
基准分析 - 确定交易市场价值
财务条款 - 预付款、里程碑付款、特许权使用费
依公司（A-Z）、协议类型和治疗领域分类的合约目录
以价值排名的主要交易
最活跃的交易撮合者
确定每笔交易的资产和条款
存取合约文件 - 深入了解交易结构
尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性
节省数百小时的研究时间

范围

"药物 "药物递送合作与授权协议" 旨在帮助读者深入了解全球主要生物製药公司在药物递送技术领域的合作趋势和合约结构。

"药物递送合作研究与授权协议" 内容：

生物製药产业药物递送交易趋势
製药和生物技术公司药物递送交易记录目录
以价值排名的主要药物递送交易
最活跃的药物递送许可协议公司
"药物递送合作研究与许可协议" 提供全面的交易记录存取权限，包括可用的合约文件。

分析合约内容有助于对以下方面进行尽职调查：

合约中具体授予或选择哪些权利？
合约实际上赋予合作伙伴哪些权利？
授予了哪些排他性权利？
交易的付款结构是怎么样的？
销售和付款如何审计？
合约期限是多久？
合约的关键条款是如何定义的？
知识产权（IPR）如何处理与归属？
谁负责商业化？
谁负责开发、供应和生产？
如何管理保密性和资讯揭露？
如何解决争议？
在什么情况下可以终止合约？
如果所有权发生变更，会发生什么事？
如何约定转让许可和分包条款？
贵公司要求哪些标准条款？
哪些标准条款会因交易对手和交易类型而异？
贵公司必须受哪个司法管辖区管辖？

引言
历年药物递送交易
最活跃的药物递送交易参与者
依交易类型划分的药物递送交易
依治疗领域划分的药物递送交易
依行业划分的药物递送交易
药物递送交易条款
- 药物递送交易总额
- 药物递送协议中的预付款
- 药物递送协议中的里程碑付款
- 药物递送特许权使用费率

第三章 - 主要药物递送交易

引言
以价值排名的顶级药物输送交易

第四章 - 最活跃的药物传输交易商

引言
最活跃的药物传输交易商
最活跃的药物输送交易公司简介

第五章 - 药物输送合约交易目录

引言
药物输送合约交易目录

第六章 - 依技术类型划分的药物输送交易

交易目录
依公司划分的药物输送交易目录 (AZ)
以交易类型划分的药物输送交易目录
依治疗领域划分的药物传输交易目录
交易类型定义
关于研究公司
当前合作伙伴关係
当前合约
目前合作伙伴的当前报告标题

简介目录

Product Code: CP2102

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1246 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse drug delivery collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

Trends in drug delivery dealmaking in the biopharma industry
Directory of drug delivery deal records covering pharmaceutical and biotechnology
The leading drug delivery deals by value
Most active drug delivery licensing dealmakers
Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery deals over the years
2.3. Most active drug delivery dealmakers
2.4. Drug delivery deals by deal type
2.5. Drug delivery deals by therapy area
2.6. Drug delivery deals by industry sector
2.7. Deal terms for drug delivery deals
- 2.7.1 Drug delivery deals headline values
- 2.7.2 Drug delivery deal upfront payments
- 2.7.3 Drug delivery deal milestone payments
- 2.7.4 Drug delivery royalty rates